Dive Brief:
- Medtronic will shutter its Santa Rosa, California, site in about two years, spokesperson Justin Paquette said Friday in an email to MedTech Dive. The decision follows a review of global operations.
- The planned closure of the site comes as the medtech giant combines its cardiac surgery and aortic businesses to create a new operating unit focused on cardiovascular surgery. The consolidation was recently announced in a LinkedIn post.
- Medtronic is also integrating its structural heart, coronary and renal denervation businesses to form an interventional cardiology therapies unit, Paquette said.
Dive Insight:
Medtronic has operated a location in Santa Rosa since acquiring stent manufacturer Arterial Vascular Engineering in 1998.
The company made the “difficult but strategic decision” to close the site after reviewing its global operations to ensure it is positioned for long-term growth and to meet the evolving needs of patients and healthcare providers, Paquette said.
Medtronic did not confirm the number of employees affected by the closure. The Press Democrat reported that 370 workers are affected.
Employees will begin to depart from the site in spring 2027, and the operation will close in spring 2028, Paquette said. The company expects no impact to customers.
Medtronic is creating the cardiovascular surgery business unit to accelerate innovation in cardiac and aortic care by partnering closely with vascular, cardiothoracic and cardiac specialists, Paquette said.
“The integration is intended to help us strengthen our focus and investment so we can continue to best serve patients across the entire continuum of cardiovascular care,” he said.
Karim Bandali, president of cardiovascular surgery, announced the unit’s formation last week on LinkedIn. Bandali previously was Medtronic’s president of cardiac surgery.
Paquette said bringing together the structural heart, coronary and renal denervation businesses to form the interventional cardiology therapies unit is an additional effort to deliver value to customers and impact to patients.
“We believe this new organizational approach will help us advance our strategy in these critical business areas,” he said.
